Genentech Joins Hunt For ‘Molecular Glue’ Drugs With Orionis
Will Aim At ‘Undruggable’ Oncology and Neurodegeneration Targets
Executive Summary
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.